界定适合主动监测的中危前列腺癌
基于瑞典国家前列腺癌登记库2009-2012年5087例根治性前列腺切除术病例,比较低危与中危前列腺癌的升级和分期上调结局。结果显示Grade Group 1且PSA 10-15 ng/ml、PSA密度<0.15 ng/ml/cm者与低危者无显著差异,而PSA>15 ng/ml或Grade Group 2者侵袭性癌风险显著增加。
要点
- Grade Group 1且PSA 10-15 ng/ml、PSA密度<0.15者主动监测结局与低危相近
- PSA>15 ng/ml或Grade Group 2者侵袭性前列腺癌风险显著增加
- 低危CAPRA评分(0-2)的Grade Group 2者升级风险近三倍
核心结论
- 将Grade Group 1的PSA阈值扩展至15 ng/ml可使更多男性选择主动监测,尤其PSA密度低时不太可能影响结局。
- 对PSA>15 ng/ml或Grade Group 2前列腺癌者提供主动监测应谨慎。
研究设计与样本
- 观察性研究,基于瑞典国家前列腺癌登记库(覆盖全国98%前列腺癌病例)。
- 2009-2012年共5087例接受根治性前列腺切除术的低危(Grade Group 1、PSA<10 ng/ml、cT2或以下)和中危(Grade Group 2、PSA 10-20 ng/ml或T2)前列腺癌男性。
- 结果在2013-2016年诊断的独立数据集中验证。
主要发现
- Grade Group 1、PSA 10-15 ng/ml且PSA密度<0.15 ng/ml/cm者与低危前列腺癌者相比,升级或不良病理发现无显著差异。
- PSA>15 ng/ml或Grade Group 2与侵袭性前列腺癌风险显著增加相关。
- 低危CAPRA评分(0-2)且Grade Group 2者相比低危CAPRA评分且Grade Group 1者,升级风险增加近三倍,不良病理风险增加两倍。
关键数值与推荐
- 低危定义:Grade Group 1、PSA<10 ng/ml、cT2或以下。
- 中危定义:Grade Group 2、PSA 10-20 ng/ml或T2。
- 基于CAPRA评分和已发表的主动监测标准比较升级和分期上调。
临床怎么用
- 对Grade Group 1且PSA 10-15 ng/ml、PSA密度<0.15 ng/ml/cm者可考虑扩大主动监测适应证。
- 对PSA>15 ng/ml或Grade Group 2前列腺癌者应谨慎提供主动监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Active surveillance of intermediate risk prostate cancer is controversial. Many active surveillance programs are limited to men with Grade Group 1 (Gleason 6) disease and prostate specific antigen less than 10 ng/ml. However, recent guidelines state that active surveillance can be considered in cases of limited Grade Group 2 (Gleason 3 + 4) despite limited data on outcomes. We compared prostatectomy outcomes between prostate cancer subgroups of intermediate risk vs low risk. MATERIALS AND METHODS: We performed an observational study in the National Prostate Cancer Register of Sweden, which includes 98% of prostate cancer cases nationwide. From 2009 to 2012 radical prostatectomy was performed in 5,087 men with low risk prostate cancer (Grade Group 1, prostate specific antigen less than 10 ng/ml and cT2 or less) and intermediate risk prostate cancer (Grade Group 2, prostate specific antigen 10 to 20 ng/ml or T2). We compared upgrading and up staging between the groups based on the CAPRA (Cancer of the Prostate Risk Assessment) scores and published active surveillance criteria. Results were validated in an independent data set of cases diagnosed from 2013 to 2016. RESULTS: Men with Grade Group 1, prostate specific antigen 10 to 15 ng/ml and prostate specific antigen density less than 0.15 ng/ml/cm did not significantly differ in upgrading or adverse pathology findings compared to men with low risk prostate cancer. Prostate specific antigen greater than 15 ng/ml or Grade Group 2 was associated with a significantly greater risk of aggressive prostate cancer. Men with low risk CAPRA scores (0 to 2) and Grade Group 2 disease were at almost threefold increased risk of upgrading and twofold increased risk of adverse pathology compared to men with low risk CAPRA, Grade Group 1 disease. CONCLUSIONS: Expanding the prostate specific antigen threshold to 15 ng/ml for Grade Group 1 prostate cancer would allow more men to elect active surveillance. This is unlikely to compromise outcomes, particularly if prostate specific antigen density is low. In contrast, caution should be exercised in offering active surveillance to men with prostate specific antigen greater than 15 ng/ml or Grade Group 2 prostate cancer.
引用
- Loeb S, Folkvaljon Y, Bratt O, et al. Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance. J Urol. 2019. PMID: 30240688. doi:10.1016/j.juro.2018.09.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。